Tscan Therapeutics, Inc.
Clinical trials sponsored by Tscan Therapeutics, Inc., explained in plain language.
A clinical-stage biotech developing T-cell receptor therapies for cancer.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Supercharged donor cells aim to stop leukemia return after transplant
⭐️ CURE ⭐️ Recruiting nowThis study tests a new approach to prevent leukemia from coming back after a stem cell transplant. It uses donor T cells that have been engineered to recognize and attack a specific target (HA-2) on leukemia cells. The trial enrolls adults with acute myeloid leukemia (AML) or mye…
Phase: PHASE3 • Sponsor: TScan Therapeutics, Inc. • Aim: ⭐️ CURE ⭐️
Last updated Jul 24, 2026 00:00 UTC
-
Supercharged donor cells aim to stop blood cancer relapse after transplant
Disease control Recruiting nowThis early-phase study tests whether specially engineered donor immune cells (TSC-100 or TSC-101) can safely reduce the risk of cancer returning after a stem cell transplant. About 75 adults with acute myeloid leukemia, myelodysplastic syndromes, or acute lymphoblastic leukemia w…
Phase: PHASE1 • Sponsor: TScan Therapeutics, Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Scientists hunt for hidden triggers of autoimmune diseases
Knowledge-focused Recruiting nowThis study collects tissue and blood samples from 300 people with autoimmune diseases like Crohn's, multiple sclerosis, and celiac disease. Researchers aim to identify the specific targets of immune cells (T cells) that cause inflammation. The goal is to discover new targets for …
Sponsor: TScan Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
15-Year study launches to monitor safety of experimental TCR-T therapy
Knowledge-focused Recruiting nowThis study follows 1,000 people who previously received an experimental cell therapy (TSC-100 or TSC-101) for blood cancers like leukemia. Researchers will track side effects and survival for up to 15 years to see if the treatment remains safe and effective over time. No new trea…
Sponsor: TScan Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:52 UTC